Equities analysts forecast that Hill-Rom Holdings, Inc. (NYSE:HRC) will post $697.28 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Hill-Rom’s earnings, with estimates ranging from $691.80 million to $700.00 million. Hill-Rom posted sales of $782.80 million during the same quarter last year, which would indicate a negative year over year growth rate of 10.9%. The company is expected to report its next quarterly earnings report on Friday, November 6th.
According to Zacks, analysts expect that Hill-Rom will report full year sales of $2.87 billion for the current year, with estimates ranging from $2.87 billion to $2.88 billion. For the next fiscal year, analysts anticipate that the business will post sales of $2.87 billion, with estimates ranging from $2.77 billion to $2.95 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Hill-Rom.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, July 31st. The medical technology company reported $1.95 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.46 by $0.49. Hill-Rom had a net margin of 7.05% and a return on equity of 25.48%. The business had revenue of $767.50 million during the quarter, compared to analysts’ expectations of $749.39 million. During the same quarter in the prior year, the business posted $1.23 earnings per share. Hill-Rom’s revenue was up 5.6% compared to the same quarter last year.
Shares of Hill-Rom stock traded down $1.41 on Monday, reaching $82.10. 527,633 shares of the stock were exchanged, compared to its average volume of 657,402. The firm’s 50 day moving average is $89.62 and its 200-day moving average is $100.20. Hill-Rom has a one year low of $72.29 and a one year high of $117.68. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.16 and a current ratio of 1.50. The firm has a market cap of $5.56 billion, a PE ratio of 26.48, a P/E/G ratio of 2.63 and a beta of 0.59.
The company also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Friday, September 18th were issued a $0.22 dividend. The ex-dividend date was Thursday, September 17th. This represents a $0.88 dividend on an annualized basis and a yield of 1.07%. Hill-Rom’s payout ratio is presently 17.32%.
Several hedge funds have recently made changes to their positions in the company. BDO Wealth Advisors LLC bought a new stake in shares of Hill-Rom during the first quarter worth about $29,000. CSat Investment Advisory L.P. boosted its position in Hill-Rom by 78.6% during the 2nd quarter. CSat Investment Advisory L.P. now owns 343 shares of the medical technology company’s stock worth $38,000 after buying an additional 151 shares during the period. FinTrust Capital Advisors LLC bought a new stake in Hill-Rom during the 2nd quarter worth approximately $52,000. Cerebellum GP LLC bought a new position in shares of Hill-Rom during the second quarter valued at $79,000. Finally, Citizens Financial Group Inc RI grew its stake in shares of Hill-Rom by 42.0% in the second quarter. Citizens Financial Group Inc RI now owns 1,032 shares of the medical technology company’s stock worth $113,000 after purchasing an additional 305 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
See Also: Why do analysts give a neutral rating?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.